4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-amine | 125383-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-amine
• CAS: 125383-30-4
• 化学式: C₁₆H₁₁BrClN₃
• 分子量: 360.64
• InChiKey: MVFYZSDJFRQYBZ-UHFFFAOYSA-N

物化性质

• 熔点：
  219-220 °C(Solv: ethanol (64-17-5); toluene (108-88-3))
• 沸点：
  556.4±60.0 °C(Predicted)
• 密度：
  1.522±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二羟基苯乙酮 、 4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-amine 在 溶剂黄146 作用下， 反应 48.0h， 生成
  参考文献：
  名称：

  In silico guided development of imine-based inhibitors for resistance-deriving kinases

  摘要：

  Two major mechanisms involved in resistant NSCLC (non-small cell lung cancer) include secondary acquired mutation in EGFR (epidermal growth factor receptor), that is, EGFR T790M and amplification of c-MET (hepatocyte growth factor receptor). Thus, already established pharmacophore models of EGFR T790M and c-MET were employed to filter-out an in-house database. Further fitness score led to the selection of imino-pyrimidine scaffold. Followed by sketching of imino-pyrimidine derivatives having varied aryl substitutions, which were then docked and subjected to molecular dynamic simulations, to study the orientations and conformations of the designed molecules in the catalytic domain. Molecules with hydrophobic interaction with mutant residue M790 were selected. Finally, MM-GBSA (Molecular Mechanics-Generalized Born Surface Area) calculations were performed, to study the effect of substitutions on the binding affinity of the double mutant EGFR towards these small molecules. Finally, the designed compounds were synthesized and evaluated for their kinase inhibitory potential using in-vitro experiments. Two compounds were found to possess sub-micromolar range inhibitory potential against EGFR (T790M), while one of the compound showed significant selective inhibitory potential against c-MET. Additionally, one compound was found to possess significant dual inhibitory potential against these target kinases.

  DOI：

  10.1080/07391102.2018.1491893
• 作为产物：
  描述：

  4-溴苯乙酮 在 双氧水 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 2.0h， 生成 4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-amine
  参考文献：
  名称：

  Bukhari, Mujahid Hussain; Siddiqui, Hamid Latif; Ashraf, Chaudhary Muhammad, Journal of the Chemical Society of Pakistan, 2011, vol. 33, # 5, p. 720 - 725

  摘要：

  DOI：

文献信息

• Ultrasound-mediated synthesis, biological evaluation, docking and in vivo acute oral toxicity study of novel indolin-2-one coupled pyrimidine derivatives
  作者：Anna Pratima G. Nikalje、Shailee V. Tiwari、Jaiprakash N. Sangshetti、Manoj D. Damale

  DOI：10.1007/s11164-018-3292-5

  日期：2018.5

  ultrasound-mediated greener synthesis of 11 novel 3-(4-(4-chlorophenyl)-6-(substituted phenyl/heteryl)pyrimidin-2-ylimino)indolin-2-one (7a–7k) derivatives. The synthesized derivatives were evaluated for their in vitro anticancer activity against a panel of selected human cancer cell lines of breast (MCF-7), cervix (HeLa), prostate (PC-3) and lung (A-549). Among the tested compounds, 7b exhibited most

  这项工作报告了11种新型3-（4-（4-氯苯基）-6-（取代的苯基/杂芳基嘧啶-2-ylimino）吲哚满-2-一（7a – 7k）衍生物的超声介导的绿色合成。评估合成的衍生物对一组选定的人类乳腺癌细胞系乳腺癌（MCF-7），宫颈（HeLa），前列腺（PC-3）和肺（A-549）的体外抗癌活性。在测试的化合物中，7b对HeLa，PC-3和A-549表现出最有希望的体外抗癌活性，GI 50分别为15.38、19.67和4.37 µM。还筛选了化合物（7a – 7k）在其GI 50时诱导癌细胞凋亡和形态变化。浓度。用7b处理HeLa，PC-3和A549癌细胞以及用7h处理MCF-7癌细胞显示出凋亡和形态学变化，例如细胞收缩，细胞壁变形和存活细胞数量减少。与RWPE-1正常前列腺上皮细胞相比，化合物7b对PC-3癌细胞系的选择性提高了近5.00倍。已经进行了分子对接研究，该研究复制了初次命中7b
• Iron Catalyzed Synthesis of Pyrimidines Under Air
  作者：Rakesh Mondal、Suman Sinha、Siuli Das、Gargi Chakraborty、Nanda D. Paul

  DOI：10.1002/adsc.201901172

  日期：2020.2.6

  Herein we report an iron‐catalyzed multicomponent dehydrogenative functionalization of alcohols to pyrimidines under atmospheric conditions. Using a well‐defined Fe(II)‐complex featuring redox noninnocent 2‐phenylazo‐(1,10‐phenanthroline) ligand, as a catalyst, a wide array of 2,4,6‐trisubstituted pyrimidines were prepared via dehydrogenative coupling of primary and secondary alcohols with amidines

  在本文中，我们报道了在大气条件下醇催化的铁催化多组分脱氢官能化为嘧啶。使用具有明确的氧化还原非纯2-苯基偶氮（1,10-菲咯啉）配体的Fe（II）络合物作为催化剂，通过伯脱氢偶联制备了各种2,4,6-三取代的嘧啶空气中在100°C下与and形成的仲醇和仲醇。进行了一些对照实验，以了解并揭示合理的反应机理。
• Ligand centered redox enabled sustainable synthesis of triazines and pyrimidines using a zinc-stabilized azo-anion radical catalyst
  作者：Siuli Das、Rakesh Mondal、Amit Kumar Guin、Nanda D. Paul

  DOI：10.1039/d1ob02428k

  日期：——

  yields. A series of control reactions were performed to predict the plausible mechanism, suggesting that the active participation of the ligand-centered redox events enables the Zn(II)-complex 1a to act as an efficient catalyst for synthesizing these N-heterocycles. Electron transfer processes occur at the azo-aromatic ligand throughout the catalytic reaction, and the Zn(II)-center serves only as a template

  在此，我们报告了以配体为中心的氧化还原控制的 Zn( II ) 催化的多组分合成嘧啶和三嗪的方法。利用以配体为中心的氧化还原事件，并使用明确定义的 Zn( II )-催化剂 ( 1a ) 轴承 ( E )-2-((4-氯苯基)二氮烯基)-1,10-菲咯啉 ( L 1a ) 作为通过脱氢醇官能化反应制备了氧化还原活性配体、多种取代的嘧啶和三嗪。嘧啶通过以下方法制备两条途径：（i）伯醇和仲醇与脒的脱氢偶联和（ii）伯醇与炔烃和脒的脱氢偶联。通过醇和脒的脱氢偶联制备三嗪。催化剂1a对多种底物具有良好的耐受性，能以中等至良好的分离产率产生所需的嘧啶和三嗪。进行了一系列控制反应来预测可能的机制，这表明以配体为中心的氧化还原事件的积极参与使得 Zn( II ) -配合物1a作为合成这些N-杂环的有效催化剂。在整个催化反应中，电子转移过程发生在偶氮芳族配体上，而 Zn( II ) 中心仅作为模板。
• Hasan, Aurangzeb; Khaleeq, Musfirah; Riaz, Uzma, Asian Journal of Chemistry, 2010, vol. 22, # 7, p. 5581 - 5587
  作者：Hasan, Aurangzeb、Khaleeq, Musfirah、Riaz, Uzma

  DOI：——

  日期：——
• Chpudhary, Prakash C.; Sharma, Hari Om; Punjabi, Pinki B., Indian Journal of Heterocyclic Chemistry, 2011, vol. 20, # 3, p. 209 - 212
  作者：Chpudhary, Prakash C.、Sharma, Hari Om、Punjabi, Pinki B.、Verma

  DOI：——

  日期：——